Skip to content

Insider · CIK 0001318485

Daniel B Soland

director

Files at ACAD (ACADIA PHARMACEUTICALS INC). First filing -, latest -.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold

Signals

This insider’s open-market buys and sells, scored.

No scored open-market trades yet.

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
May 29, 2025ACAD
ACADIA PHARMACEUTICALS INC
MOption exercise
Common Stock
+9,387--44,041Jun 2, 2025
May 29, 2025ACAD
ACADIA PHARMACEUTICALS INC
MOption exercise
Restricted Stock Unitsderivative
-9,387$0.00$00Jun 2, 2025
May 29, 2025ACAD
ACADIA PHARMACEUTICALS INC
AGrant or award
Director Stock Options (Right to Buy)derivative
+13,793$0.00$013,793Jun 2, 2025
May 29, 2025ACAD
ACADIA PHARMACEUTICALS INC
AGrant or award
Restricted Stock Unitsderivative
+8,107$0.00$08,107Jun 2, 2025

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Daniel B Soland: insider trades and track record | InsiderTell